Literature DB >> 24156221

Sensitization to the mammalian oligosaccharide galactose-alpha-1,3-galactose (alpha-gal): experience in a Flemish case series.

D G Ebo1, M Faber, V Sabato, J Leysen, A Gadisseur, C H Bridts, L S De Clerck.   

Abstract

BACKGROUND: Recent observations have disclosed that the galactose-alpha (1,3)-galactose (alpha-gal) moiety of non-primate glycoproteins can constitute a target for meat allergy.
OBJECTIVE: To describe adults with allergic reactions to mammalian meat, dairy products and gelatin. To investigate whether patients could demonstrate sensitization to activated recombinant human coagulation factor VII ectapog alpha that is produced in baby hamster kidney cells.
METHODS: Ten adults with mammalian meat, dairy products and gelatin allergies were examined using quantification of specific IgE and/or skin prick test for red meat, milk, milk components, gelatin, cetuximab and eptacog alpha.
RESULTS: Most patients demonstrate quite typical clinical histories and serological profiles, with anti-alpha-gal titers varying from less than 1% to over 25% of total serum IgE. All patients demonstrate negative sIgE for gelatin, except the patient with a genuine gelatin allergy. All patients also demonstrated a negative sIgE to recombinant milk components casein, lactalbumin and lactoglobulin. Specific IgE to eptacog was positive in 5 out of the 9 patients sensitized to alpha-gal and none of the 10 control individuals.
CONCLUSION: This series confirms the importance of the alpha-gal carbohydrate moiety as a potential target for allergy to mammalian meat, dairy products and gelatin (oral, topical or parenteral) in a Flemish population of meat allergic adults. It also confirms in vitro tests to mammalian meat generally to be more reliable than mammalian meat skin tests, but that diagnosis can benefit from skin testing with cetuximab. Specific IgE to gelatin is far too insensitive to diagnose alphaa-gal related gelatin allergy. IgE binding studies indicate a potential risk of alpha-gal-containing human recombinant proteins produced in mammalians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24156221     DOI: 10.2143/ACB.3278

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  7 in total

Review 1.  Carbohydrates as allergens.

Authors:  Scott P Commins
Journal:  Curr Allergy Asthma Rep       Date:  2015-01       Impact factor: 4.806

Review 2.  Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose.

Authors:  Thomas A E Platts-Mills; Alexander J Schuyler; Alice E W Hoyt; Scott P Commins
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

3.  Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients.

Authors:  Scott P Commins
Journal:  Expert Rev Clin Immunol       Date:  2020-07-08       Impact factor: 4.473

Review 4.  In Vitro Diagnosis of Immediate Drug Hypersensitivity Anno 2017: Potentials and Limitations.

Authors:  I I Decuyper; E A Mangodt; A L Van Gasse; K Claesen; A Uyttebroek; M Faber; V Sabato; C H Bridts; C Mertens; M M Hagendorens; L S De Clerck; Didier G Ebo
Journal:  Drugs R D       Date:  2017-06

Review 5.  Hazardous Medications in Children with Egg, Red Meat, Gelatin, Fish, and Cow's Milk Allergy.

Authors:  Sule Caglayan-Sozmen; Angelica Santoro; Francesca Cipriani; Carla Mastrorilli; Giampaolo Ricci; Carlo Caffarelli
Journal:  Medicina (Kaunas)       Date:  2019-08-19       Impact factor: 2.430

Review 6.  Alpha-Gal Syndrome in Children: Peculiarities of a "Tick-Borne" Allergic Disease.

Authors:  Francesca Saretta; Mattia Giovannini; Francesca Mori; Stefania Arasi; Lucia Liotti; Luca Pecoraro; Simona Barni; Riccardo Castagnoli; Carla Mastrorilli; Lucia Caminiti; Gian Luigi Marseglia; Elio Novembre
Journal:  Front Pediatr       Date:  2021-12-23       Impact factor: 3.418

Review 7.  The red meat allergy syndrome in Sweden.

Authors:  Danijela Apostolovic; Thi Anh Thu Tran; Maria Starkhammar; Sara Sánchez-Vidaurre; Carl Hamsten; Marianne Van Hage
Journal:  Allergo J Int       Date:  2016-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.